HilleVax Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • HilleVax's estimated annual revenue is currently $8.8M per year.(i)
  • HilleVax's estimated revenue per employee is $155,000

Employee Data

  • HilleVax has 57 Employees.(i)
  • HilleVax grew their employee count by -55% last year.

HilleVax's People

NameTitleEmail/Phone
1
CEO, President and ChairReveal Email/Phone
2
COO & Co-FounderReveal Email/Phone
3
General Counsel and Chief Administrative OfficerReveal Email/Phone
4
Chief Technology OfficerReveal Email/Phone
5
Chief Financial OfficerReveal Email/Phone
6
Chief Operating OfficerReveal Email/Phone
7
Chief Operating OfficerReveal Email/Phone
8
Chief Medical OfficerReveal Email/Phone
9
VP QualityReveal Email/Phone
10
SVPReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$2.8M18-33%N/AN/A
#10
$9.1M59-9%N/AN/A
Add Company

What Is HilleVax?

keywords:N/A

N/A

Total Funding

57

Number of Employees

$8.8M

Revenue (est)

-55%

Employee Growth %

N/A

Valuation

N/A

Accelerator

HilleVax News

2022-04-17 - Norovirus vaccine developer HilleVax files for $100M IPO

HilleVax has been developing vaccine called HIL-214 for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection...

2022-04-13 - HilleVax Targets $100 Million IPO For Acute Gastroenteritis Vaccine

HilleVax has booked fair market value investment of $158 million in convertible promissory notes from investors including Frazier Life Sciences...

2022-04-06 - HilleVax, a Biopharma Developing Vaccines, Is Going Public

HilleVax, which was formed by Takeda Pharmaceutical and private-equity firm Frazier Healthcare Partners, is going public.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M57-8%N/A
#2
$10.5M578%N/A
#3
$7.5M57-5%N/A
#4
$7.7M57-10%N/A
#5
$14.9M5721%N/A